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The excitatory neurotransmitter glutamate is essential in basal ganglia motor circuits 
and has long been thought to contribute to cell death and degeneration in Parkinson’s 
disease (PD). While previous research has shown a significant role of NMDA and 
AMPA receptors in both excitotoxicity and PD, the third class of ionotropic glutamate 
receptors, kainate receptors, have been less well studied. Given the expression of 
kainate receptor subunits GluK1-GluK3 in key PD-related brain regions, it has been 
suggested that GluK1-GluK3 may contribute to excitotoxic cell loss. Therefore the 
neuroprotective potential of the kainate receptor antagonist UBP310 in animal models 
of PD was investigated in this study. Stereological quantification revealed 
administration of UBP310 significantly increased survival of dopaminergic and total 
neuron populations in the substantia nigra pars compacta in the acute MPTP mouse 
model of PD. In contrast, UBP310 was unable to rescue MPTP-induced loss of 
dopamine levels or dopamine transporter expression in the striatum. Furthermore, 
deletion of GluK1, GluK2 or GluK3 had no effect on MPTP or UBP310-mediated 
effects across all measures. Interestingly, UBP310 did not attenuate cell loss in the 
midbrain induced by intrastriatal 6-OHDA toxicity. These results indicate UBP310 
provides neuroprotection in the midbrain against MPTP neurotoxicity that is not 
dependent on specific kainate receptor subunits. 
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MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NeuN, neuronal nuclei;  PD, 
Parkinson’s disease; SNpc, substantia nigra pars compacta; STN, subthalamic nucleus; TH, 
tyrosine hydroxylase;  
1. Introduction 
The progressive neurodegenerative disorder Parkinson’s disease (PD) continues to 
represent a significant health and economic burden. While the use of levodopa remains 
an effective strategy in the treatment of the motor symptoms of PD, degeneration of the 
nigrostriatal tract and subsequent loss of dopamine (DA) within the striatum continues 
to occur. A vast amount of research has therefore focused on identifying the 
mechanisms underlying this degeneration with the aim of developing novel treatments 
to halt disease progression. 
 
Excitotoxicity, mediated by glutamate receptors at synapses, has long been thought to 
contribute to cell death and degeneration in PD due to the critical function of glutamate 
in the basal ganglia (BG) motor circuit (Blandini et al. 1996, Blandini 2010). Studies 
initially focused on the ionotropic NMDA and AMPA subtypes of receptors as potential 
drug targets for PD, as they mediate the majority of fast excitatory transmission in the 
brain and have long been implicated in excitotoxicity (Klockgether et al. 1989, 
Koutsilieri et al. 2007, Ambrosi et al. 2014). Despite the evidence antagonists of these 
receptor subtypes reduce PD pathophysiology in animal models (Loschmann et al. 
1991, Turski et al. 1991, Loschmann et al. 1992, Wachtel et al. 1992, Konitsiotis et al. 
2000, Blandini et al. 2001), translation of these drugs to the clinic was not similarly 
successful as they often result in severe adverse side effects such as psychosis, 
hallucinations, and impaired learning (Lipton 2006, Johnson et al. 2009), likely due to 
the effects of altering glutamatergic signaling in healthy areas of the brain.  
 
The observation that glutamate is important in PD, together with the failure to translate 
NMDA and AMPA receptor antagonists has led to a search for alternative approaches 
to target excitatory neurotransmission. Metabotropic glutamate receptors (mGluRs), 
have emerged as an alternative target to modifying excitotoxicity as this receptor family 
plays a modulatory role rather than being involved in fast excitatory neurotransmission 
(Johnson et al. 2009). As such, mGluR antagonists have been extensively studied as a 
potential therapeutic alternative in PD (Johnson et al. 2009, Stayte et al. 2014) as 
targeting them may potentially have less side effects than targeting NMDA or AMPA 
receptors.  
 
While there has been strong attention on mGluRs for PD, the role of the third class of 
ionotropic glutamate receptors, kainate receptors (KARs), is less well studied, in part 
because of a lack of specific pharmacological tools to probe their function. It is known 
that KARs, like mGluRs, play a modulatory role at synapses, albeit through different 
mechanisms (Fernandes et al. 2009). Comprised of heteromeric combinations of 
subunits GluK1-GluK5, KARs are located both postsynaptically where they mediate a 
component of the excitatory postsynaptic current, and presynaptically where they bi-
directionally modify synapse efficacy at both excitatory and inhibitory synapses (Mulle 
et al. 1998, Contractor et al. 2000, Vissel et al. 2001, Jin et al. 2007). There are currently 
limited studies of KARs in human or animal models of PD, however expression of these 
receptors has been demonstrated in both the mouse (Bischoff et al. 1997) and rat brain 
(Wisden et al. 1993, Bahn et al. 1994, Ghasemzadeh et al. 1996, Wullner et al. 1997), 
with varying subunit compositions that often include high proportions of the GluK1-
GluK3 subunits. In the mouse brain in particular, GluK1 and GluK3 appear to be highly 
localized to the substantia nigra pars compacta (SNpc), while GluK2 is abundant in the 
striatum and subthalamic nucleus (STN). Meanwhile GluK4 and GluK5 display little 
to no expression in these regions. Following these important studies, it was postulated 
that KARs, particularly those containing GluK1-GluK3, may be of potential relevance 
to PD, given they are located in areas critical to both nigrostriatal degeneration and 
motor function (Wisden et al. 1993, Bahn et al. 1994, Bischoff et al. 1997, Wullner et 
al. 1997). Therefore KAR antagonists may provide a more selective way to ameliorate 
glutamate receptor-mediated degeneration compared to NMDA and AMPA antagonists 
since KARs are primarily modulatory, less abundant, and less ubiquitous. However, 
direct investigation of this drug class and the receptors they target, specifically in PD, 
has been lacking. 
 
More recently, the development of KAR specific drugs has allowed for investigations 
of KAR functions. One such drug is the willardine derivative UBP310, considered to 
be a GluK1-selective antagonist with nanomolar affinity (Mayer et al. 2006, Dolman et 
al. 2007) though it also potently antagonizes recombinant homomeric GluK3 receptors 
in HEK293 cells and CA3 pyramidal cells of wild type mice and rats (Perrais et al. 
2009), and displays some actions on GluK2 in a mouse model of temporal lobe epilepsy 
(Peret et al. 2014). In this study we provide the first evidence that 
intracerebroventricular (i.c.v) administration of UBP310 provides significant 
protection of midbrain neurons from degeneration in the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) mouse model of PD, and provide evidence that this effect 
is not dependent on specific KAR subunits.  
 
 
2. Materials and Methods 
 
2.1 Animals 
C57BL/6 male mice from Australian BioResources (Moss Vale, Australia) or GluK1-/-
, GluK2-/-, or GluK3-/- male mice and their littermate wildtypes (WTs) were obtained at 
11 weeks of age.  Mice were housed at a maximum five mice per cage for 1 week, until 
the study began, at which time mice were housed individually. Animals that did not 
undergo surgical procedures remained in group housing for the duration of the study. 
Mice were kept on a 12-hour light/dark cycle and access to food and water ad libitum. 
All animal procedures were performed with the approval of the Garvan Institute and St. 
Vincent’s Hospital Animal Ethics Committee under approval numbers 15/07 and 18/16, 
in accordance with the Australian National Health and Medical Research Council 
animal experimentation guidelines and the local Code of Practice for the Care and Use 
of Animals for Scientific Purposes (2004). All surgery was performed under 
ketamine/xylazil anesthesia, and all efforts were made to minimize suffering. 
 
2.2 Osmotic micropump implantation 
Animals were anesthetized with a mixture of 8.7 mg/ml ketamine (Provet) and 2 mg/ml 
xylazil (Provet) and placed in a stereotaxic apparatus (Kopf Instruments). Osmotic 
micropumps (Model 1007D; Alzet) were filled with 0.8834 μg/μl (5.3 μg total daily 
dose) of UBP310 (Tocris) or vehicle control (10% DMSO) and implanted 
subcutaneously along the back of the neck. An infusion cannula (PlasticsOne) 
connected to the micropump was placed in the right lateral ventricle at AP -0.2, ML 
+1.0, DV -2.8 relative to bregma for all MPTP and drug measurement studies. For all 
6-OHDA studies the infusion cannula was placed in the left lateral ventricle at AP -0.2, 
ML -1.0, DV -2.8 to ensure cannula did not impede subsequent lesioning and the pump 
was removed 1 week later and the cannula tubing sealed with heat. All stereotaxic 
coordinates were based on the Paxinos atlas for the mouse brain (Paxinos et al. 2001). 
 
2.3 MPTP administration 
The day after pump implantation, animals received subcutaneous injections of 20 
mg/kg of MPTP (at 2hr intervals x 4 doses; Sigma Aldrich) or vehicle (saline) and 
placed on heat pads during the injection period and the following 24h to reduce 
mortality. All mice were euthanized 8 days after the final administration of MPTP or 
saline. 
 
2.4 Unilateral 6-OHDA lesioning 
The day after pump implantation, animals were anesthetized with a mixture of ketamine 
and xylazil and placed in a stereotaxic apparatus as described above. Mice were then 
injected with 2 x 2 μl of 3 mg/ml (total 12 μg) of 6-hydroxydopamine (6-OHDA; Sigma 
Aldrich) in 0.02% ascorbic acid (sham) in the right sensorimotor striatum at the 
following coordinates: AP +1.0, ML +2.1, DV -2.9 and AP +0.3, ML +2.3, DV -2.9, 
relative to bregma and the dural surface as previously described (Stayte et al. 2015) and 
based on the Paxinos atlas for the mouse brain (Paxinos et al. 2001). 6-OHDA (or 
0.02% ascorbic acid control) was injected at a rate of 0.5 μl/min and the syringe left in 
place for 2 min after each injection to allow for complete diffusion. All mice were 
euthanized 3 weeks after lesioning. 
 
2.5 Immunohistochemistry 
Mice were anesthetized and transcardially perfused with ice-cold phosphate-buffered 
saline (PBS) and 4% paraformaldehyde. Brains were harvested and processed as 
described in detail previously (Stayte et al. 2015). Sections were incubated in the 
following primary antibodies: monoclonal mouse tyrosine hydroxylase (TH 1:1000, 
Sigma Aldrich cat # T2928), monoclonal mouse neuronal nuclei (NeuN 1:500, Merck 
cat # MAB377) for 72 hours at 4°C. All sections were then incubated in the respective 
biotin-labeled secondary antibodies (1:250, Abcam cat # AB6813, ThermoFisher 
Scientific, Cat # B-2770) overnight at 4°C followed by incubation in avidin-biotin 
complex (Vector Laboratories) at room temperature for 1 h. TH immunolabeling was 
detected with 3,3’-Diaminobenzidine (DAB, Abacus) until desired staining achieved. 
NeuN immunolabeling was detected with DAB intensified with nickel ammonium 
sulfate and counterstained with polyclonal rabbit anti-TH (1:1000, Merck cat # AB152) 
that was detected with Nova-Red (Abacus) to outline the substantia nigra region. 
 
2.6 Stereology 
Quantification of SNpc cell populations was performed using the optical fractionator 
method and the use of Stereo Investigator 7 software (MBF Bioscience, USA). 
Sampling parameters for quantification of TH and NeuN positive cells were used as 
previously described (Stayte et al. 2015, Stayte et al. 2017). 
 
2.7 Catecholamine analysis 
Animals were euthanized by cervical dislocation 8 days after the administration of 
MPTP or saline, the brains removed and the striatum rapidly dissected out and snap 
frozen. Striata were analyzed for dopamine (DA), 3,4-dihydroxyphenylacetic acid 
(DOPAC), and homovanillic acid (HVA) via HPLC as described previously (Stayte et 
al. 2015). Catecholamine levels were standardized to protein levels measured via 
Bradford assay and recorded as ng/μg of protein. All standards for the Bradford assay 
were prepared in freshly made 0.2M PCA + 0.1% L-cysteine. 
 
2.8 Western blotting 
Animals were euthanized by cervical dislocation 8 days after the administration of 
MPTP or saline, the brains removed and the striatum rapidly dissected out and snap 
frozen. Striata were sonicated in protease inhibitor cocktail (Sigma Aldrich) diluted at 
a concentration of 1:1000 in RIPA buffer (Sigma Aldrich) and centrifuged at 16,000g 
for 15 minutes at 4°C. For all samples, 10 μg was loaded onto 4-12% Bis-Tris gels 
(ThermoFisher Scientific) and protein was separated by running the gel at 180V for 
approximately 45 min. Following transfer to PVDF membranes (ThermoFisher 
Scientific), membranes were blocked in 10% skim milk solution for 1 h at room 
temperature and then incubated in 0.1% BSA solution containing monoclonal rat 
dopamine transporter (DAT) antibody (Merck cat # MAB369) at a concentration of 
1:1000 and kept at 4°C overnight on an orbital shaker. Following washing in buffer 
containing 1 x TBS buffer without triton + 0.1% Tween 20 for 1 h, membranes were 
incubated in 5% skim milk solution containing goat anti-rat HRP secondary antibody 
(Abcam cat # AB97057) at a concentration of 1:1000 for 1 h at room temperature. 
Membranes were then visualized using Novex ECL Chemiluminescent Substrate 
Reagent Kit (ThermoFisher Scientific) and visualized in a Chemidoc MP Imaging 
System (Bio-Rad). Images were then analyzed using Image Lab software (Bio-Rad). 
All membranes were then stripped and re-probed with monoclonal rabbit anti-GAPDH 
(Cell Signaling cat # 2188) at a concentration of 1:1000. Raw values were standardized 
to GAPDH and then adjusted with the values taken from control mice.  
 
2.9 UBP310 measurements 
Animals were euthanized by cervical dislocation 24, 48, 72, or 168 h after UBP310 
pump implantation and whole brain harvested and snap frozen. Drug naïve mice acted 
as controls. 100 mg of freeze-dried and powdered tissue was extracted by sonication 
for 15 min in 1 ml methanol after spiking with 5 ng of internal standard UBP302 
(Tocris). This is a close structural analogue of the analyte molecule and was selected as 
an affordable internal standard. After extraction the samples were centrifuged at 15,000 
rpm for 10 min and the supernatant collected and reduced to dryness in a vacuum 
centrifuge. For analysis, samples were suspended in 100 μl of 1:1 methanol:0.1% 
formic acid in water and transferred to sample vials for mass spectrometric 
interrogation. Prior to LC-MS analysis the mass spectrometer (ThermoFisher Scientific 
Quantum Access) was tuned for maximum sensitivity using continual syringe infusion 
of a solution containing 100 ng/ml of the two UBP molecules. After tuning the tube 
lens was held at 145V, the skimmer at 0V, vaporizer temperature at 200°C, capillary 
temperature at 250°C, sheath gas flow of 20 arbitrary units (au), auxiliary gas flow of 
10 au. Optimal selected reaction monitoring transitions were determined for each 
compound. UBP302 was detected using 334>183 at 16V with the additional qualifying 
transitions of 334>316 at 10V and 334>116 at 39V. UBP310 was detected using 
354>197 at 20V, with the additional qualifiers at 354>308 at 13V and 354>336 at 12V. 
10 μl of resuspended sample was injected using a PAL autosampler system (CTC). 
Samples were chromatographed on a Waters BEH C18 50 x 2.1mm x 1.9 μm UHPLC 
column using a gradient of 0.1% formic acid in water against acetonitrile. Solvent was 
delivered at 400 μl/min using an Accela Pump (ThermoFisher Scientific). The solvent 
composition was held at 100% A for 0.5 min, ramped to 0% A at 4.5 min, held at 0% 
A until 5 min and then immediately returned to 100% A and held until 7 min for 
requilibration. Both compounds eluted at 3 min with excellent peak shape using this 
program. The system was controlled through XCalibur software. Quantification was 
performed using an external calibration curve over the range 0-10 ng on column, 
corrected using the ISTD. Prior to analysis of treated brain samples the system was 
established as fit-for-purpose by analyzing recoveries from spiked brain material. 
 
2.10 Striatal MPP+ measurements 
Animals were anesthetized with a ketamine/xylazil mixture 90 min after the final MPTP 
injection followed by cervical dislocation. The brains were removed and the striatum 
rapidly dissected and snap frozen. Accurately weighed tissue was resuspended at 30 
mg/ml in 12% acetic acid in MilliQ water. Samples were extracted by probe sonication 
for 30 s followed by vortex mixing. After extraction the samples were centrifuged at 
15,000 rpm for 10 min and the supernatant collected, diluted 10 times in extraction 
solvent and transferred to plastic sample vials for mass spectrometric interrogation. 
Prior to LC-MS analysis the mass spectrometer (ThermoFisher Scientific Quantum 
Access) was tuned for maximum sensitivity using continual syringe infusion of a 
solution containing 100 ng/ml of the MPP+ standard (Sigma Aldrich cat # D048). After 
tuning the tube lens was held at 83V, the skimmer at 0V, vaporizer temperature at 
200°C, capillary temperature at 250°C, sheath gas flow of 20 arbitrary units (au), 
auxiliary gas flow of 10 au. Optimal selected reaction monitoring transitions were 
determined – MPP+ was detected using 170>128 at 33V with the additional qualifying 
transitions of 170>127 at 33V and 170>77 at 47V. 20 μl of sample extract was injected 
using a PAL autosampler system (CTC). Samples were chromatographed on a Thermo 
Acclaim C30 100 x 2.1mm x 3μm UHPLC column using a gradient of 0.1% formic 
acid in water against acetonitrile. Solvent was delivered at 400 μl/min using an Accela 
Pump (ThermoFisher Scientific). The solvent composition was held at 100% A for 0.5 
min, ramped to 0% A at 4.5 min, held at 0% A until 5 min and then immediately 
returned to 100% A and held until 7 min for requilibration. MPP+ eluted at around 3 
min with excellent peak shape using this program. The system was controlled through 
XCalibur software. Quantification was performed using an 8 point external calibration 
curve over the range 0-500 pg on column. Prior to analysis of treated brain samples, the 
system was established as fit-for-purpose by analyzing recoveries from spiked drug 
naïve brain material. 
 
2.11 Statistical analysis 
All data were expressed as mean ± SEM. All statistical analysis was performed using 
GraphPad Prism Version 6.0 (GraphPad Software, Inc). Difference between means was 
assessed, as appropriate, by unpaired t test or one or two way ANOVA followed by 
Tukey or Bonferroni post hoc analysis. 
 
3. Results 
3.1 Osmotic i.c.v. administration results in measurable quantities of UBP310 in 
the brain 
Investigating the potential neuroprotective effects of UBP310 required administering 
the drug via osmotic micropumps attached to cannula implanted into the ventricles. To 
ensure this delivery method resulted in availability of UBP310 to the brain parenchyma, 
whole brain tissue was harvested at 24, 48, 72, or 168 h after pump implantation. One-
way ANOVA of the LC-MS analysis revealed a significant effect of time on UBP310 
levels (F(4,30)=5.078, p=0.003). Tukey’s post hoc tests revealed a significant increase in 
UBP310 levels compared to drug naïve mice at 24 (p=0.0039), 48 (p=0.0091), 72 
(p=0.0375) and 168 h (p=0.0066) however no difference between drug treated animals 
at any timepoint was observed (Figure 1), indicating i.c.v. administration was sufficient 
to deliver measurable quantities of UBP310 that were unchanged across time. 
 
 
Figure 1. UBP310 levels following intracerebroventricular administration. (A) 
Experimental timeline. (B) LC-MS analysis of UBP310 levels in whole brain tissue 
revealed measureable quantities of UBP310 that was unchanged over time. All values 
represent mean ± SEM. *p<0.05, **p<0.01 (compared to drug naïve mice). N = 7-
8/group. 
 
3.2 UBP310 increases survival of nigral neurons following MPTP 
To determine the potential neuroprotective effect of UBP310, the number of TH 
positive cells in the SNpc region was quantified via stereology as a measurement of 
dopaminergic neuron survival. As expected, MPTP administration resulted in a 
significant loss of dopaminergic neurons (F(1,37)=9.296, p=0.0042), as animals 
receiving vehicle (10% DMSO) displayed fewer TH positive cells following MPTP 
compared to their saline controls (p=0.0097 Figure 2B and 2C). However, a significant 
effect of drug treatment was found (F(1,37)=4.953, p=0.0322) with i.c.v. infusion of 
UBP310 significantly attenuating this effect, increasing the number of surviving TH 
positive neurons against MPTP-induced toxicity (p=0.0202), without altering baseline 
numbers in saline treated animals (p>0.9999). Furthermore, the number of 
dopaminergic neurons in animals receiving UBP310 and MPTP was comparable to 
those receiving UBP310 and saline (p=0.4669), suggesting a potent neuroprotective 
effect of UBP310. 
 
To confirm the increased number of surviving TH positive cells with UBP310 treatment 
was not due to changes in TH expression, as this phenotypic marker can decrease during 
times of cell stress in the absence of cell death, the number of total neurons in the SNpc 
was also quantified (Figure 2D). Administration of MPTP significantly decreased the 
population of total neurons (F(1,35)=4.685; p=0.0373), with animals receiving vehicle 
displaying a reduction in NeuN positive cells following MPTP compared to their saline 
controls (p=0.0227), however UBP310 was able to attenuate this loss (p=0.0024) 
without altering the baseline number of total neurons in the SNpc. Furthermore, the 














































with MPTP, compared to their saline controls. Combined, these results indicate a 
protection of total neuron numbers with UBP310. Additionally, this neuroprotection is 
not due to UBP310 altering the metabolism of MPTP, with no significant differences 
found in striatal MPP+ levels (p=0.5369) between DMSO (378 pg/mg ± 28.95) and 
UBP310 (346 pg/mg ± 36.15) treated animals. 
 
Figure 2. UBP310 is neuroprotective against MPTP-induced toxicity in the SNpc. 
(A) Experimental timeline. (B) Representative images of TH immunoreactive cells in 
the SNpc. Stereological analysis in the SNpc 1 week after MPTP administration 
revealed i.c.v. infusion of UBP310 significantly increases survival of (C) TH positive 
and (D) NeuN positive cells. All values represent the mean ± SEM. *p<0.05, **p<0.01. 
Scale bar represents 200 μm. N = 7-13/group 
 
3.3 Effects of UBP310 in the midbrain of KAR subunit knockout mice 
While originally identified as a GluK1 specific antagonist (Mayer et al. 2006, Dolman 
et al. 2007), subsequent studies revealed UBP310 also has actions on GluK2 (Perrais et 
al. 2009) and GluK3 (Peret et al. 2014). Further, the majority of in vivo studies 
investigating these effects focused primarily on the effects of UBP310 on hippocampal 
neurons (Pinheiro et al. 2013, Grosenbaugh et al. 2018). Therefore to identify which of 
these subunits contribute to the previously observed neuroprotective effects of UBP310 
in the midbrain, UBP310 was administered to GluK1-/-, GluK2-/-, or GluK3-/- mice or 
their littermate WTs in the MPTP model. A cohort of KAR subunit knockout animals 
were also analyzed in the absence of UBP310 treatment to determine any effect of 
individual KAR subunits on MPTP-mediated toxicity. 
 
3.3.1 The neuroprotective effects of UBP310 in the midbrain are not altered upon 
GluK1 subunit deletion 
Quantification of TH positive cells revealed no difference between GluK1-/- and WT 
animals in the saline treated group (p>0.9999), indicating deletion of the GluK1 subunit 
does not alter baseline levels of dopaminergic neurons in the SNpc. Two-way ANOVA 
revealed a significant effect of treatment on the number of surviving TH positive 
neurons in the SNpc (F(2,48)=16.59, p<0.0001). Similar to our previous results, UBP310 
significantly increased the number of surviving neurons in WT animals following 
MPTP (p=0.0056), with animals receiving UBP310 displaying cell populations that 
were not significantly different from their saline controls (p>0.9999) suggesting a 
potent neuroprotective effect (Figure 3A). However no significant effect of genotype 
(F(1,48)=0.595, p=0.443) was found, with GluK1-/- mice continuing to display loss of TH 
positive cells after MPTP (p=0.0013) and subsequent increased survival in the presence 
of UBP310 (p=0.0100). As shown in Figure 3B, analysis of NeuN positive cells 
revealed a similar overall effect of treatment (F(2,49)=14.19, p<0.0001), with MPTP 
causing a significant loss of neurons and UBP310 significantly increasing survival in 
both GluK1-/- and WT animals. No significant difference was found between genotypes 
within any of the treatment groups (F(1,49)=0.05444, p=0.8165). Together these results 
indicate that deletion of the GluK1 subunit does not alter the neuroprotective effects of 
UBP310 in the midbrain. 
 
Figure 3. The effect of UBP310 in the SNpc of KAR subunit knockout mice. 
Stereological analysis of TH immunoreactive and NeuN immunoreactive populations 
in the SNpc revealed no alterations in the neuroprotective effect of UBP310 against 
MPTP-induced toxicity in GluK1-/- (A, B), GluK2-/- (C, D), or GluK3-/- (E, F) animals. 
All values represent the mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
N = 8-13/group. 
 
3.3.2 The neuroprotective effects of UBP310 in the midbrain are not altered upon 
GluK2 subunit deletion 
No significant difference in the number of TH positive cell populations between GluK2-




































































































































































deletion of the GluK2 subunit does not alter baseline levels of dopaminergic neurons 
in the SNpc. An overall effect of treatment on surviving cells was found (F(2,55)=12.16, 
p<0.0001), with both MPTP and UBP310 maintaining their deleterious and 
neuroprotective effects, respectively (Figure 3C). Post hoc analysis revealed animals 
treated with UBP310 had numbers of TH cells that were not statistically different from 
their saline treated controls (GluK2-/- p>0.9999, WT p>0.9999), again suggesting a 
potent neuroprotective effect of UBP310. Two-way ANOVA with Bonferroni post hoc 
tests showed no effect of genotype (F(1,55)=0.0334, p=0.8557) on TH positive cell 
numbers, with no significant difference between GluK2-/- and WT animals in both the 
MPTP (p>0.9999) and UBP310 treated groups (p>0.9999). Quantification of NeuN 
positive cells yielded similar results (Figure 3D), with UBP310 inhibiting MPTP-
induced cell loss (F(2,56)=12.42, p<0.0001), an effect that was maintained in both 
genotypes (F(1,56)=0.4053, p=0.5269). Together these results indicate that deletion of 
the GluK2 subunit does not alter the neuroprotective effects of UBP310 in the midbrain. 
 
3.3.3 The neuroprotective effects of UBP310 in the midbrain are not altered upon 
GluK3 subunit deletion 
No significant differences in the number of TH positive cells between GluK3-/- mice 
and their littermate WTs in the saline group (p>0.9999) demonstrates deletion of GluK3 
does not alter baseline level of dopaminergic neurons in the SNpc. As expected, an 
overall effect of treatment was found (F(2,53)=15.54, p<0.0001) with post hoc analysis 
confirming MPTP administration resulted in a significant loss of TH positive cells in 
both GluK3-/- (p=0.0081) and WT animals (p=0.0008). This deficit was rescued with 
UBP310 administration (GluK3-/- p=0.0058, WT p=0.0118), with UBP310 treated 
animals displaying cell numbers that were not significantly different from their saline 
controls (Figure 3E). However no significant effect of genotype was found 
(F(1,53)=0.06284, p=0.8030), with GluK3-/- and WT animals displaying similar cell 
populations across all treatment groups. As shown in Figure 3F, quantification of NeuN 
positive cells revealed a similar overall effect of treatment (F(2,49)=16.33, p<0.0001), 
with MPTP causing a significant loss of neurons and UBP310 significantly increasing 
survival in both GluK3-/- and WT animals while no effect of genotype was found within 
any of the treatment groups (F(1,49)=0.3218, p=0.5731). Together these results indicate 
that deletion of the GluK3 subunit does not alter the neuroprotective effects of UBP310 
in the midbrain. 
 
3.4 Effects of UBP310 in the striatum of KAR subunit knockout mice 
3.4.1 Deletion of the GluK1 subunit does not alter MPTP or UBP310-mediated 
effects in the striatum 
Similar to human PD, the loss of dopaminergic neurons with the SNpc in the MPTP 
mouse model results in a subsequent loss of DA in the striatum, thus a neuroprotection 
of nigral neurons would likely result in a corresponding protection of striatal DA levels. 
Therefore striatal tissue was harvested and quantification of DA, DOPAC and HVA via 
HPLC coupled to an electrochemical detector was conducted. Two-way ANOVA with 
Bonferroni post hoc analysis revealed MPTP induced a significant loss of DA levels 
(F(2,17)=49.55, p<0.0001) that was unable to be rescued with UBP310 treatment (Figure 
4A), contrasting the previous neuroprotective effects in the midbrain. Interestingly, no 
difference was found between GluK1-/- and WT animals across any of the treatment 
groups (F(1,17)=0.07649, p=0.7854), implicating GluK1 deletion does not alter baseline 
DA or subsequent MPTP or UBP310-mediated effects. Analysis of DOPAC levels 
showed a significant interaction (F(2,17)=4.722, p=0.0234) between treatment 
(F(2,17)=63.75; p<0.0001) and genotype (F(1,17)=1.226; p=0.2837). While GluK1-/- 
animals had higher baseline levels of DOPAC compared to their WT littermates 
(p=0.0217), this difference was not maintained following MPTP or UBP310 treatment 
(Figure 4B). Furthermore, GluK1 deletion had no effect on HVA (F(1,17)=0.03876; 
p=0.8463) or DA/HVA (F(1,17)=0.9492; p=0.3436) levels across all 3 treatment groups. 
Given the important role the DA transporter (DAT) plays in maintaining sufficient DA 
levels for release into the synaptic cleft, striatal DAT protein levels were also quantified 
via immunoblotting. Corresponding to the loss of striatal catecholamines, MPTP 
induced a significant loss of DAT (F(2,47)=66.31, p<0.0001) compared to control groups 
(Figure 4E and 4F), an effect that was not rescued with UBP310 treatment or altered 
by genotype (F(1,47)=0.002879; p=0.957). Together, these results demonstrate GluK1 
deletion does not alter MPTP or UBP310-mediated effects in the striatum. 
 
 
Figure 4. The effect of UBP310 in the striatum of GluK1-/- mice. (A) HPLC 
quantification of catecholamine levels revealed no effect of UBP310 or GluK1 deletion 
on striatal DA levels. (B) While GluK1-/- animals had higher baseline DOPAC levels 
there was no effect of GluK1 deletion on MPTP or UBP310-mediated effects. No effect 
of UBP310 or GluK1 deletion was found on (C) HVA levels or (D) the ratio of DA to 
HVA. (E) Representative bands of DAT and GAPDH expression from striatal protein 
extracts where “+” denotes WT and “-” denotes GluK1 deletion. (F) Quantification of 
DAT protein expression normalized to GAPDH revealed no effect of UBP310 or 
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****p<0.0001 (compared to saline controls), #p<0.05 (compared to WT saline). N = 3-
4/group for HPLC analysis, n = 7-10/group for DAT analysis. 
 
3.4.2 Deletion of the GluK2 subunit does not alter MPTP or UBP310-mediated 
effects in the striatum 
No difference in striatal DA levels was found between GluK2-/- and WT animals in the 
saline treated group, suggesting GluK2 deletion does not affect baseline DA levels. An 
absence of GluK2-mediated effects on DA levels was further evident in no significant 
difference between GluK2-/- and WT animals in both the MPTP and UBP310 treated 
groups (Figure 5A), despite a significant MPTP-induced depletion of DA (Treatment 
F(2,18)=27.94; p<0.0001 Genotype F(1,18)=0.07495; p=0.7874). Analysis of the 
metabolites of DA revealed a significant loss of DOPAC in WT but not GluK2-/- 
animals following MPTP (Figure 5B), despite a strong trend towards reduction in 
GluK2-/- mice (p=0.0517). However, a significant loss of DOPAC was found in both 
WT and GluK2-/- animals treated with UBP310. Similar to results in the GluK1-/- 
experiments, GluK2 deletion had no effect on HVA (F(1,18)=0.1334; p=0.7192 Figure 
5C) or DA/HVA (F(1,18)=0.5367; p=0.4732 Figure 5D) levels across all 3 treatment 
groups. MPTP-mediated loss of DAT was also unchanged by both UBP310 treatment 
(F(2,47)=47.55; p<0.0001 Figure 5E and 5F) or genotype (F(1,47)=0.9486; p=0.3351). 
Together, these results demonstrate GluK2 deletion does not alter MPTP or UBP310-
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Figure 5. The effect of UBP310 in the striatum of GluK2-/- mice. HPLC 
quantification of catecholamine levels revealed no effect of UBP310 or GluK2 deletion 
on striatal (A) DA, (B) DOPAC or (C) HVA levels or (D) the ratio of DA to HVA. (E) 
Representative bands of DAT and GAPDH expression from striatal protein extracts 
where “+” denotes WT and “-” denotes GluK2 deletion. (F) Quantification of DAT 
protein expression normalized to GAPDH revealed no effect of UBP310 or GluK2 
deletion. All values represent the mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. N = 4/group for HPLC analysis, n = 7-11/group for DAT analysis. 
 
3.4.3 Deletion of the GluK3 subunit does not alter MPTP or UBP310-mediated 
effects in the striatum 
As expected, MPTP administration resulted in a significant reduction of striatal DA 
levels in both GluK3-/- and WT animals, an effect that was not altered with UBP310 
treatment (F(2,17)=37.44; p<0.0001 Figure 6A). While there was no difference in 
baseline levels of DA between both GluK3-/- and WT mice, there was also no effect of 
GluK3 deletion in both MPTP and UBP310 treated groups (F(1,17)=0.8304; p=0.3749). 
An absence of GluK3-mediated effects was maintained when analyzing DOPAC 
(F(1,17)=2.674; p=0.1204 Figure 6B), HVA (F(1,17)=1.763; p=0.2019 Figure 6C) and 
DA/HVA levels (F(1,17)=0.2079; p=0.6542 Figure 6D). Analysis of striatal DAT 
expression also revealed a similar result, with loss of striatal dopaminergic fibres in 
both the MPTP and UBP310 treated groups (F(2,53)=47.31; p<0.0001 Figure 6E and 6F) 
that was unchanged between GluK3-/- and WT animals (F(1,53)=0.8918; p=0.3493). 
Together, these results demonstrate GluK3 deletion does not alter MPTP or UBP310-
mediated effects in the striatum. 
 
 
Figure 6. The effect of UBP310 in the striatum of GluK3-/- mice. HPLC 
quantification of catecholamine levels revealed no effect of UBP310 or GluK3 deletion 
on striatal (A) DA, (B) DOPAC or (C) HVA levels or (D) the ratio of DA to HVA. (E) 
Representative bands of DAT and GAPDH expression from striatal protein extracts 
where “+” denotes WT and “-” denotes GluK3 deletion. (F) Quantification of DAT 
protein expression normalized to GAPDH revealed no effect of UBP310 or GluK3 
deletion. All values represent the mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. N = 3-4/group for HPLC analysis, n = 8-13/group for DAT analysis. 
 
3.5 UBP310 is not neuroprotective against 6-OHDA-induced toxicity 
To investigate if UBP310 also exerts a neuroprotective effect in the 6-OHDA mouse 
model of PD, dopaminergic and total neuron numbers were quantified 3 weeks after 
intrastriatal injection of 6-OHDA. Sham animals receiving UBP310 showed no 
significant differences in the number of TH positive cells compared to sham animals 
receiving vehicle (p=0.7882), again demonstrating UBP310 does not alter baseline 
levels of dopamine neurons in this model. As expected, 6-OHDA resulted in a 
significant loss of dopaminergic neurons (F(1,24)=71.47, p<0.0001), however UBP310 
did not protect against this loss (F(1,24)=0.1749, p=0.6795), with no significant 
difference between UBP310 and vehicle treated animals (p=0.3149) in the number of 
surviving dopaminergic neurons (Figure 7B). Analysis of the number of NeuN positive 
cells in the SNpc revealed an interaction between toxin and drug treatment 
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neuron loss. However Bonferroni post hoc analysis demonstrated no significant 
difference in the number of NeuN positive cells between UBP310 and vehicle treated 
animals in both the sham (p=0.1649) and 6-OHDA (p=0.0956) groups (Figure 7C). 
These results suggest that unlike in the MPTP model of PD, UBP310 is not protective 
against intrastriatal 6-OHDA-induced degeneration.  
 
Figure 7. UBP310 does not protect midbrain neurons against 6-OHDA-induced 
toxicity. (A) Experimental timeline. (B) Stereological analysis of TH immunoreactive 
neurons in the SNpc 3 weeks after intrastriatal injection of 6-OHDA or ascorbic acid 
control revealed no effect of UBP310 on dopaminergic neuron populations. (C) 
Stereological analysis of NeuN immunoreactive neurons in the SNpc 3 weeks after 
intrastriatal injection of 6-OHDA or ascorbic acid control revealed no effect of UBP310 
on dopaminergic neuron populations. All values represent the mean ± SEM. 
***p<0.001, ****p<0.0001. N = 7/group 
 
4. Discussion 
Owing to its critical role in synaptic transmission within BG motor circuits and 
evidence of aberrant glutamate signaling in DA-depleted systems, glutamate and its 
associated receptors have long been linked to the pathophysiology of PD. As a direct 
result, antagonists against specific glutamate receptor families have been tested as 
potential therapeutics in both animal models and human clinical trials (Johnson et al. 
2009). These studies have largely focused on NMDA and AMPA receptor antagonists, 
with limited information regarding the contribution of KARs to PD pathophysiology. 
Research on the neurobiology of KARs has rapidly expanded within the past few 
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development of pharmacological and genetic tools capable of specifically targeting 
KARs. This has allowed a distinction between the role of AMPA receptors and KARs 
to be made and led to a growing understanding of the role that KARs not only play in 
the healthy brain, but in disorders in which abnormalities in glutamatergic 
neurotransmission are considered to be an important factor, such as PD. The current 
study is the first to demonstrate that antagonizing KARs is neuroprotective in the 
midbrain, in an animal model of PD. 
 
Although there is, at present, no perfect preclinical model capable of replicating the 
entirety of the human PD phenotype, animal models have proven useful for testing 
novel therapeutic strategies. Both the 6-OHDA and MPTP mouse models employed in 
this study, for instance, are well-established models for investigating potential 
neuroprotective agents for PD as they replicate the selective death of dopaminergic 
neurons within the SNpc and subsequent loss of DA in the striatum. Following 
demonstration that intracerebroventricular infusion of UBP310 resulted in measurable 
and stable quantities of the antagonist in the brain parenchyma, the major finding from 
this work was that UBP310 administration offered significant protection of 
dopaminergic neuron populations in the SNpc against MPTP-induced toxicity. 
 
Considering its critical role in DA synthesis, TH has long been the standard marker of 
dopaminergic structures of the brain. However, it is necessary to validate neuron 
numbers using multiple markers, as TH expression has been illustrated to decrease 
during times of cell stress, including after MPTP administration (Xu et al. 2005, Kozina 
et al. 2014). Thus, we corroborated our TH measurements through the quantification of 
NeuN positive cell numbers, a prototypical marker of neuronal populations. As 
expected, the numbers of NeuN positive neurons were consistently higher across all 
groups when compared to the gross number of TH positive cells, which is consistent 
with NeuN expression in both dopaminergic and non-dopaminergic populations in the 
SNpc. Importantly however, the significant increase in survival of NeuN positive cells 
corroborated the increased survival of TH positive cells, providing further evidence that 
UBP310 was indeed neuroprotective. 
 
KARs consist of tetrameric combinations of subunits GluK1-GluK5, with GluK1-
GluK3 able to form functional homomeric or heteromeric receptors, unlike GluK4 and 
GluK5 which require GluK1-GluK3 to be functional. Multiple in situ hybridization 
studies have revealed differential expression of individual KAR subunits within the BG 
of both mice (Bischoff et al. 1997) and rats (Wisden et al. 1993, Bahn et al. 1994, 
Ghasemzadeh et al. 1996, Wullner et al. 1997), often including high proportions of 
GluK1-GluK3 compared to GluK4-GluK5. Despite its initial development as a GluK1 
specific antagonist (Mayer et al. 2006, Dolman et al. 2007), subsequent in vitro and in 
vivo studies provided evidence UBP310 exerts additional actions on GluK2 and GluK3 
(Perrais et al. 2009, Peret et al. 2014).  
 
In the current study, global deletion of the GluK1, GluK2, or GluK3 subunit did not 
alter the survival of dopaminergic or total neuron populations in the SNpc in any of the 
treatment groups. Both GluK1 and GluK3 have been shown to be highly expressed in 
the mouse SNpc (Bischoff et al. 1997), likely contributing to the neuroprotective effects 
of UBP310 through direct inhibition of glutamate-mediated cell death in this region. 
Injection of the GluK1 agonist ATPA into the SNpc results in ipsilateral turning 
behavior in rats and subsequent loss of TH positive cells (Vivo et al. 2002), thus it is 
interesting GluK1-/- animals did not display neuroprotection against MPTP alone, 
however this may be due to the differences in GluK1 activation between ATPA and 
MPTP. While GluK2 has only moderate expression in the SNpc of the mouse, it is 
highly expressed in the STN (Bischoff et al. 1997). In the presence of aberrant 
glutamate signaling, as occurs in PD, it is thought increased firing of STN inputs to the 
SNpc contributes further to DA neuron loss. Thus antagonism of GluK2 in the STN via 
UBP310 through reducing aberrant BG excitability may contribute to the protection of 
nigral cell populations, together with direct antagonism of GluK1 and GluK3 
containing receptors on DA neurons. Therefore, it remains possible that the 
neuroprotective effects of UBP310 in the midbrain against MPTP-induced toxicity may 
result from its actions on all 3 subunits or some combination thereof.  
 
The MPTP mouse model not only induces significant levels of cell death in the SNpc, 
but also replicates the subsequent loss of DA within the striatum that occurs in PD, an 
effect that is reproduced in this study. Despite a significant protection of nigral cell 
populations, UBP310 was unable to attenuate the loss of DA in the striatum, an effect 
that was not altered in any of the KAR subunit knockout animals. While it could be 
hypothesized this may be due to UBP310 simply increasing the metabolism of DA, thus 
reducing the amount of DA present at the time of analysis, this is unlikely as UBP310 
also had no effect on the level of the DA metabolites DOPAC and HVA, nor the ratio 
of DA:HVA. In a study in which MPP+ was injected into the striatum of rats, followed 
by various glutamate receptor antagonists, it was found the NDMA antagonists MK-
801 and 7-CI-KYN did not lower the DA deficit induced by MPP+ while the non-
selective glutamate antagonist kynurenate and the AMPA/kainate receptor antagonist 
CNQX both partially attenuated DA loss (Merino et al. 1999). Interestingly, NBQX 
resulted in a similar protection of DA levels when compared to CNQX and kynurenate 
(Merino et al. 1999), and given the greater affinity of NBQX for AMPARs over KARs, 
it is likely protection of striatal DA levels in each treatment group can be attributed to 
antagonism of AMPARs in this brain region. This is in accordance with the highest 
levels of AMPAR expression in the BG being found in the striatum (Albin et al. 1992, 
Ball et al. 1994, Bernard et al. 1996) while there is limited expression of KAR subunits 
in this area (Bischoff et al. 1997). The lack of UBP310 to provide neuroprotection of 
nigral neuron populations against 6-OHDA supports this hypothesis, given the striatal 
injection site of the toxin and the subsequent retrograde degeneration it induces 
(Blandini et al. 2007, Alvarez-Fischer et al. 2008).  
 
Additionally, UBP310 was unable to attenuate loss of dopaminergic fibres in the 
striatum in this study, mirroring the loss of DA across treatment groups. While this 
effect may also be due to the differential expression of KARs in this brain region, the 
loss of dendrites of nigral neurons has been suggested as an early indicator of 
neurodegeneration (Bywood et al. 2000) and non-human primate studies utilizing 
MPP+ have further supported this idea by suggesting degenerative events are initiated 
in the striatum (Herkenham et al. 1991). Thus future studies examining the survival of 
the nigrostriatal tract at a longer timepoint after MPTP, coupled with 
electrophysiological investigations of the functionality of the surviving neurons, would 
aid in determining if UBP310 only offers neuroprotection in the midbrain or merely 
slows the degeneration of the neurons at the level of the soma. In contrast, this 
discrepancy between midbrain and striatum has been previously shown in studies 
utilizing MPTP (Liberatore et al. 1999, Feng et al. 2002, Stayte et al. 2017) and 
knockout animals (Bodea et al. 2014), suggesting regional-specific effects are indeed 
possible (Herkenham et al. 1991, Bywood et al. 2000).  
 
The findings from this study raise a number of interesting points. Firstly, the 
neuroprotective effects of UBP310 appear to be localized to the midbrain, an effect 
likely due to the combined antagonism of GluK1 and GluK3 within the SNpc itself and 
potential antagonism of GluK2 within the STN. Direct application of UBP310 to 
various BG regions rather than via the ventricles as performed in this study would 
provide further clarification of the subunit-specific mechanisms involved in UBP310’s 
effects. Secondly, previous studies determining the effects of UBP310 on synaptic 
transmission have been performed primarily on hippocampal neurons (Pinheiro et al. 
2013, Grosenbaugh et al. 2018), given the high density of KARS in this region (Mulle 
et al. 2000, Isaac et al. 2004). Similar electrophysiological experiments conducted in 
BG neurons and PD models would not only identify if UBP310 alters the functionality 
of neurons, but how the drug might also modulate the balance between excitatory and 
inhibitory signaling within the BG and PD, a subject that is likely to be exceptionally 
interesting. Thirdly, despite detection of specific KAR subunits within the mouse and 
rat BG (Wisden et al. 1993, Bischoff et al. 1997, Wullner et al. 1997), clarification 
regarding the expression of GluK1-GluK5 in human BG and any subsequent changes 
associated with PD remains to be fully understood. Autoradiographic detection of 
[3H]kainate has revealed in human postmortem tissue with no evidence of disease that 
KARs are present in PD related brain regions such as the SN, caudate putamen, 
thalamic nuclei and both the internal and external segments of the globus pallidus (Ball 
et al. 1994). However limited anatomical resolution of [3H]kainate binding in this study 
raises the potential that KAR expression can be found in additional BG regions. It also 
cannot be ruled out that changes to KAR subunit expression may have occurred within 
the present study in response to select deletion of GluK1-GluK3. As KAR subunits are 
able to form heteromeric receptors, knockout of a single subunit may not alter the 
receptor itself as the remaining subunits can form viable KARs. Furthermore, failure of 
a single subunit deletion to replicate the effect of UBP310 does not rule out the drug 
working via an action on KARs. Finally, we have primarily focused on the effects of 
UBP310 on kainate receptors and subsequently, on the glutamatergic system, however 
future studies could explore other potential mechanisms outside of glutamate signaling 
as additional drivers of UBP310-mediated neuroprotection. 
 
5. Conclusion 
Glutamate-mediated mechanisms have long been thought to contribute to cell death and 
degeneration in PD, historically leading to the development of NMDA and AMPA 
receptor antagonists as potential neuroprotective drugs. However, translation of these 
treatments to the clinic has not always been successful due to the unintentional side 
effects on fast synaptic neurotransmission in healthy parts of the brain. The findings in 
this study demonstrating UBP310 has a neuroprotective role against MPTP-induced 
toxicity in the midbrain suggest that KARs warrant further investigation as an 
alternative therapeutic strategy for blocking glutamate-mediated cell death in PD. 
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